Patient characteristics
| BARFOT | Leiden EAC | |
|---|---|---|
| Total patients (n) | 784 | 820 |
| Total HAQ assessments (n) | 3951 | 2523 |
| Maximum follow-up (years) | 8 | 5 |
| Year of diagnosis | 1993–1999 | 1993–2010 |
| Female, n (%) | 515 (65.7) | 550 (67.1) |
| Age at inclusion in years, mean (SD) | 57.6 (15.6) | 56.6 (15.6) |
| Auto-antibodies | ||
| anti-CarP positive, n (%) | 278 (35.5) | 374 (45.6) |
| ACPA positive, n (%) | 452 (57.7) | 423 (51.6) |
| RF positive, n (%) | 443 (56.5) | 474 (57.8) |
ACPA, anticitrullinated peptide antibodies; anti-CarP, anticarbamylated protein antibodies; BARFOT, Better Anti-Rheumatic PharmacOTherapy; EAC, Early Arthritis Clinic; HAQ, health assessment questionnaire; RF, rheumatoid factor.
Within the BARFOT cohort, HAQ was assessed at 6 months, 1, 2, 5 and 8 years. Within the EAC cohort, HAQ was assessed yearly up to 5 years of follow-up.